5-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-1H-benzo[d]imidazol-2(3H)-one | 1354031-65-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 5-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-1H-benzo[d]imidazol-2(3H)-one
• 英文别名: 5-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butoxy]-1,3-dihydrobenzimidazol-2-one
• CAS: 1354031-65-4
• 化学式: C₂₁H₂₄Cl₂N₄O₂
• 分子量: 435.353
• InChiKey: LROJLXGQKUBROL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  29
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  56.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2,3-二氯溴苯 在 tris-(dibenzylideneacetone)dipalladium(0) 盐酸 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 sodium iodide 、 sodium t-butanolate 作用下， 以 乙酸乙酯 、 甲苯 、 乙腈 为溶剂， 反应 2.0h， 生成 5-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-1H-benzo[d]imidazol-2(3H)-one
  参考文献：
  名称：

  [EN] FUNCTIONALLY SELECTIVE LIGANDS OF DOPAMINE D2 RECEPTORS
  [FR] LIGANDS FONCTIONNELLEMENT SÉLECTIFS DES RÉCEPTEURS D2 DE DOPAMINE

  摘要：

  公开号：

  WO2012003418A3

文献信息

• Novel Functionally Selective Ligands of Dopamine D2 Receptors
  申请人：Jin Jian

  公开号：US20130137679A1

  公开（公告）日：2013-05-30

  The present invention relates to novel functionally selective ligands of dopamine D2 receptors, FIG. 1 including agonists, antagonists, and inverse agonists. The invention further relates to the use of these compounds for treating central nervous system disorders related to D2 receptors.

  本发明涉及多巴胺D2受体的新型功能选择性配体，包括激动剂、拮抗剂和反向激动剂，其中图1为配体结构。本发明还涉及使用这些化合物治疗与D2受体相关的中枢神经系统疾病。
• Structure–Functional Selectivity Relationship Studies of β-Arrestin-Biased Dopamine D₂Receptor Agonists
  作者：Xin Chen、Maria F. Sassano、Lianyou Zheng、Vincent Setola、Meng Chen、Xu Bai、Stephen V. Frye、William C. Wetsel、Bryan L. Roth、Jian Jin

  DOI：10.1021/jm300603y

  日期：2012.8.23

  Functionally selective G protein-coupled receptor (GPCR) ligands, which differentially modulate canonical and noncanonical signaling, are extremely useful for elucidating key signal transduction pathways essential for both the therapeutic actions and side effects of drugs. However, few such ligands have been created, and very little purposeful attention has been devoted to studying what we term: "structure-functional selectivity relationships" (SFSR). We recently disclosed the first beta-arrestin-biased dopamine D-2 receptor (D2R) agonists UNC9975 (44) and UNC9994 (36), which have robust in vivo antipsychotic drug-like activities. Here we report the first comprehensive SFSR studies focused on exploring four regions of the aripiprazole scaffold, which resulted in the discovery of these beta-arrestin-biased D2R agonists. These studies provide a successful proof-of-concept for how functionally selective ligands can be discovered.
• US9156822B2
  申请人：——

  公开号：US9156822B2

  公开（公告）日：2015-10-13